Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.

Equities researchers at Zacks Research lifted their FY2025 earnings per share estimates for shares of Bruker in a research ...

Bruker Co. (NASDAQ:BRKR – Get Free Report) has received a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. Five research ...

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore ...

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...

Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.

Organic revenue growth - Bruker Scientific Instruments (BSI): 4.5% versus 3.3% estimated by two analysts on average. Organic revenue growth - Bruker Energy & Supercon Technologies (BEST): -2.8% ...